ELI LILLY WKN: 858560 ISIN: US5324571083 Forum: Aktien Thema: Hauptdiskussion

$LLY Q4 Results: • Revenue: $13.53B, +45% YoY (Est: $13.45B) • Trulicity: $1.25B, -25% YoY (Est: $1.36B) • Mounjaro: $3.53B • Zepbound: $1.91B, +52% QoQ • Humalog: $619.9M, +69% YoY (Est: $500.1M) • Taltz: $952.0M, +21% YoY (Est: $943.3M) • Verzenio: $1.56B, +36% YoY (Est: $1.55B) • Adj EPS: $5.32 vs. $2.49 YoY • R&D Expenses: $3.02B, +18% YoY (Est: $3.02B) 2025 Forecast: • Adj EPS: $22.50-$24.00 (Est: $23.17) https://x.com/DeItaone/status/1887468743871111624?t=S-CLeiyCuJ_YDrr6RgtzVg&s=19

$LLY vs. $NVO. #Obesity https://x.com/doepke_michel/status/1887469928833245579?t=B_MKtYaSsjQ95eDdzayP-g&s=19

$LLY Key events for 2025 Important to highlight; Lilly anticipates key readout with their next obesity candidate: - Retatrutide for obesity and OA of the knee (TRIUMPH-4] - Also, Tirzepatide cardiovascular outcomes https://x.com/PharmDabbler/status/1887475103090307281?t=0MfQatigzOfYIh8V8H-0_w&s=19

https://x.com/PharmDabbler/status/1887472530996535610?t=8Gc8bjBs_LAQflpvNU0_2A&s=19

$LLY reports full Q4 2024 financial results and provides 2025 guidance - Revenue increased 45% to $13.53B - EPS increased 114% to $5.32 - Gross margin increased 47% to $11.13B - Mounjaro: $3.53B - Zepbound: $1.91B, +52% QoQ 2025 Guidance - Revenue $58B-$61B - EPS $22.50-$24.00

Es war ironisch. Leider geht es trotz guter Zahlen regelmäßig runter.

Ich schätze heute werden die 900 Dollar geknackt.

Warum soll das bei dem Ausblick verkauft werden, wenn dann ist es nur von kurzer Dauer um die Long Positionen auszuknocken oder um tiefer einzusteigen

Meinst du 15:30?

Dann kauf ich gleich nach 😅

Also nachher abverkauf? 😉

Na bitte was will man mehr 😊

$LLY reported good earnings results today with a double beat: ✅Revenue: $13.53B vs. $13.43B expected (+45% Y/Y) ✅EPS: $5.32 vs. $5.08 expected (+102% Y/Y) ✅ GLP-1 drugs, Mounjaro and Zepbound, are rapidly capturing market share in the booming obesity and diabetes treatment sector. ✅A strong pipeline in Alzheimer’s, oncology, and autoimmune treatments. The company’s Alzheimer’s drug, donanemab, is awaiting FDA approval and could be a multi-billion-dollar opportunity. ✅Revenue and earnings have soared, with over 40% year-over-year growth fueled by GLP-1 drugs. ❌ $NVO, the maker of Ozempic and Wegovy, is a major competitor, and potential new entrants could pressure Eli Lilly’s pricing power and growth. ❌Trades at a premium valuation, with a P/E ratio above 70. Any slowdown in GLP-1 sales or negative trial results could lead to sharp stock declines as expectations are sky-high. #LLY #StockMarket #stocks #stockmarketcrash #Investments #earnings https://x.com/Investing_Table/status/1887469472610492562?t=lHFUp2pxN5B9OYP1UBoxaQ&s=19

ELI LILLY $LLY JUST REPORTED EARNINGS EPS of $5.32 beating expectations of $5.06 Revenue of $13.53B beating expectations of $13.45B

💩das war jetzt gar nicht auf meinem Radar... sonst hätte ich wahrscheinlich 2st nachgekauft 🤦

Hier wird es bald abgehen